2015
CBM-06IMMUNE BIOMARKER RESULTS FROM A TRIAL OF NIVOLUMAB ± IPILIMUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA: CHECKMATE-143
Lowther D, Weinhold K, Reap E, Vlahovic G, Omuro A, Sahebjam S, Baehring J, Voloschin A, Cloughesy T, Lim M, Coric V, Latek R, Simon J, Lerner B, Raddassi K, Hafler D, Sampson J. CBM-06IMMUNE BIOMARKER RESULTS FROM A TRIAL OF NIVOLUMAB ± IPILIMUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA: CHECKMATE-143. Neuro-Oncology 2015, 17: v70-v70. PMCID: PMC4638710, DOI: 10.1093/neuonc/nov211.06.Peer-Reviewed Original ResearchPreliminary safety and activity of nivolumab and its combination with ipilimumab in recurrent glioblastoma (GBM): CHECKMATE-143.
Sampson J, Vlahovic G, Sahebjam S, Omuro A, Baehring J, Hafler D, Voloschin A, Paliwal P, Grosso J, Coric V, Cloughesy T, Lim M, Reardon D. Preliminary safety and activity of nivolumab and its combination with ipilimumab in recurrent glioblastoma (GBM): CHECKMATE-143. Journal Of Clinical Oncology 2015, 33: 3010-3010. DOI: 10.1200/jco.2015.33.15_suppl.3010.Peer-Reviewed Original Research
2014
Randomized phase IIb study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) alone or in combination with ipilimumab versus bevacizumab in patients (pts) with recurrent glioblastoma (GBM).
Sampson J, Vlahovic G, Desjardins A, Friedman H, Baehring J, Hafler D, Rollin L, Coric V, Perez S, Reardon D. Randomized phase IIb study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) alone or in combination with ipilimumab versus bevacizumab in patients (pts) with recurrent glioblastoma (GBM). Journal Of Clinical Oncology 2014, 32: tps2101-tps2101. DOI: 10.1200/jco.2014.32.15_suppl.tps2101.Peer-Reviewed Original Research